Phil Gross

Background

About Phil Gross

I am currently a Dermatology Medical Specialist at Regeneron, responsible for the launch & promotion of Dupixent - a first-in-class biologic therapy - to both Allergy and Dermatology Specialists in the Nashville, TN area. In 2018 I was proud to be a member of Dupixent’s first class Regeneron Cup winners. Prior to joining Regeneron, I was an Immunology Sales Specialist at Novartis, involved in the launch and promotion of Cosentyx - a first-in-class biologic therapy - to both Dermatology and Rheumatology Specialists in TN & AR. My goals are simple: to parallel the growth of this and other innovative products with that of my own career in sales & sales management. In 2004, I joined the Amgen IBU and for the next 9 years, promoted Enbrel, a sub-Q biologic for the treatment of RA, PsA, As, JIA & PsO. Additionally, While taking part in the launch and promotion of Prolia, sub-Q biologic for the treatment of PMO, I gained a firm grasp of the Buy & Bill process. While at Amgen, I earned ACT Level status, held numerous training & leadership positions and, having completed Amgen's Management Development Program, served as Interim District Manager for the Tennessee District in 2012. My strengths are simple but solid- Strong Relationship & Rapport Building Skills: based equally upon personality and the value I bring to my accounts- Strategic Thinking: built upon experience and keen awareness of potential changes in the marketplace; once an issue is identified, analyzing all possible benefits & risks and then outlining 'next steps'- Clinical Acumen: earned through a deep desire to maintain credibility with my customers while striving to be viewed as a true practice consultant- Attention to Follow-Up: learned through trial & error and is of paramount importance in creating value & credibility in the eyes of customers. In the end, the ability and willingness to adapt are core attributes that have afforded me the opportunities I have been given, as well as the successes that I have earned.